RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Small molecule neuropeptide S and melanocortin 4 receptor ligands as potential treatments for substance use disorders
Blough, B., & Namjoshi, O. (2020). Small molecule neuropeptide S and melanocortin 4 receptor ligands as potential treatments for substance use disorders. In M. A. Nader, & Y. L. Hurd (Eds.), Substance Use Disorders: From Etiology to Treatment (1st ed., Vol. 258, pp. 61-87). Springer, Cham. Advance online publication. https://doi.org/10.1007/164_2019_313
There is a vital need for novel approaches and biological targets for drug discovery and development. Treatment strategies for substance use disorders (SUDs) to date have been mostly ineffective other than substitution-like therapeutics. Two such targets are the peptide G-protein-coupled receptors neuropeptide S (NPS) and melanocortin 4 (MC4). Preclinical evidence suggests that antagonists, inverse agonists, or negative allosteric modulators of these receptors might be novel therapeutics for SUDs. NPS is a relatively unexplored receptor with high potential for treating SUD. MC4 has a strong link to early-onset obesity, and emerging evidence suggests significant overlap between food-maintained and drug-maintained behaviors making MC4 an intriguing target for SUD. This chapter provides an overview of the literature in relation to the roles of NPS and MC4 in drug-seeking behaviors and then provides a medicinal chemistry-based survey of the small molecule ligands for each receptor.